Can DCGI approved Molnupiravir bolster India's fight against COVID?
Advertisement
New Delhi: As countries prepare themselves to fight a possible 'next wave'. The new variant – Omicron has been making headline and a surge in Covid-19 cases are evident.
According to a study based on population-level evidence, the recently identified Omicron variant of SARS-CoV-2 is associated with a substantial ability to evade immunity from prior Covid-19 infection. Omicron is also considered to be three times more transmissible than the Delta variant.
One cannot ignore the worst possible threat the new variant poses. In this continuous fight against the Covid-19, many scientists and pharma companies have come together and are working relentlessly to transform the Covid-19 treatment. Amongst many treatment options available, Molnupiravir is drawing attention amongst the medical fraternity.
The Drug Controller General of India (DCGI) has given its nod to Molnupiravir for Emergency Use Authorisation (EUA) for the treatment of adult patients with Covid-19 and who have high risk of progression of the disease.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.